Erica Schwartz, nominated by President Trump to lead the Centers for Disease Control and Prevention (CDC), faced tough questions during her Senate confirmation hearing about her ability to resist political pressure from Health Secretary Robert F. Kennedy Jr.
Both Democrats and Republican committee chairman Bill Cassidy expressed frustration at Schwartz’s responses. Cassidy repeatedly questioned whether Schwartz would safeguard the CDC from political interference. Her predecessor, Susan Monarez, was removed from her position shortly after challenging Kennedy’s vaccine policies. Schwartz promised ‘radical transparency’ and assured the committee she would not compromise on scientific integrity. Yet, she avoided direct answers regarding actions she might take if Kennedy instructed her to take steps not supported by scientific evidence.
Schwartz stated, ‘The secretary absolutely will allow me to be the CDC director.’ When probed about simply endorsing vaccine decisions from Kennedy’s CDC advisory panel, Schwartz insisted Kennedy would not impose such demands.
Senator Tim Kaine highlighted concerns by referencing similar commitments made by Monarez during her confirmation, which ultimately influenced his vote against her. Senator Maggie Hassan questioned Schwartz’s stance on a scenario where HHS might instruct her to halt a flu vaccine promotion amidst a severe epidemic—a situation Kennedy actually mandated previously. Schwartz avoided hypotheticals, leading Hassan to counter that it was a reality from Kennedy’s past actions.
Cassidy, who had supported Kennedy despite reservations, has emerged as a primary GOP critic following his electoral defeat. He remained discontented with Schwartz’s replies, remarking, ‘You can be CDC director and just take orders. We need a CDC director that will actually defend against problematic claims undermining vaccine confidence.’
Though Schwartz affirmed vaccines do not cause autism and recognized no evidence otherwise, her reluctance to remove controversial language inserted by Kennedy on the CDC website signaled ongoing concerns.
Shaughnessy Naughton, president of 314 Action, criticized Schwartz’s performance, saying, ‘Her hearing was deeply disappointing—she failed to demonstrate prioritizing public health over politics.’
The Hill’s Healthcare newsletter, compiled by Nathaniel Weixel and Joseph Choi, continues to monitor the intersection of Washington’s policies and healthcare impacts. The Hill Insider digital subscription is set to launch in July 2026, offering comprehensive access.
Essential Reads
Policy impacts on healthcare sector developments:
- Trump’s recent health nominees, including Erica Schwartz, exhibited hesitance to diverge from administration views during Senate hearings.
- Acting attorney general Todd Blanche vowed action to restrict mail-based abortion medication availability.
- The CDC reported nearly 7,000 possible cyclosporiasis cases, a significant increase from the previous year.
Content from our sponsor
America’s leadership in medicine development benefits every citizen by providing new medicines three years sooner than other high-income countries. Policies mirroring foreign price controls could jeopardize access to treatments.
In Other News
Smoke from wildfires in Canada forced evacuations across the Midwest and Northeast. Over 100 fires burn in Canada, with a notable one surrounding a train crew in northern Ontario.
Around the Nation
- California passed a bill allowing anonymity for patients receiving abortion pills.
- Missouri saw a 25% drop in ACA marketplace enrollments due to rising costs.
- North Dakota reported a 309% surge in syphilis cases over five years.
What We’re Reading
- States target big businesses with employees on Medicaid facing lost funding.
- The FDA’s biologics center seeks stability under a new leader after recent challenges.
- U.S. military plans to test service members’ testosterone levels, Pete Hegseth reports.
You’ve caught up with the key healthcare updates. See you in the next issue!
Leave a Reply